PETMED EXPRESS INC
12.07%
2,579,696
1040130
Jun 28, 2026
Jun 29, 2026, 07:36 AM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| SilverCape Investments Limited | CO | 12.07% | 2,579,696 | 2,579,696 | 0 |
| Peter Kennedy | CO | 12.07% | 2,579,696 | 0 | 2,579,696 |
Disclosure Items (7)
Common Stock, $.001 Par Value
PETMED EXPRESS INC
420 South Congress Avenue, Delray Beach, FL, 33445
Item 2 of the Prior Statement is not being amended by this Amendment No. 2.
Item 2 of the Prior Statement is not being amended by this Amendment No. 2.
Item 2 of the Prior Statement is not being amended by this Amendment No. 2.
Item 2 of the Prior Statement is not being amended by this Amendment No. 2.
Item 2 of the Prior Statement is not being amended by this Amendment No. 2.
Item 3 of the of the Prior Statement is not being amended by this Amendment No. 2.
Item 5(a) of the Prior Statement is hereby amended and restated in its entirety as follows. As of the filing date of this Amendment No. 2, SilverCape is the holder of record of 2,579,696 shares of Common Stock, representing approximately 12.07% of the shares of Common Stock. The percentages used in this Amendment No. 2 are calculated based on 21,365,782 shares of Common Stock outstanding as of May 22, 2026, as last reported by the Issuer in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026. Kennedy, as the managing director of SilverCape, has voting and investment power with respect to the Common Stock held by SilverCape. Kennedy disclaims any beneficial ownership of the Common Stock beneficially owned by SilverCape.
Item 5(b) is not being amended by this Amendment No. 2.
Item 5(c) is not being amended by this Amendment No. 2.
Item 5(d) is not being amended by this Amendment No. 2.
Item 5(e) is not being amended by this Amendment No. 2.
Item 6 of the Prior Statement is hereby amended and restated as follows: The information set forth in Item 4 of this Amendment No. 2 is incorporated herein by reference. On June 29, 2026, the Reporting Persons submitted the Letter to the Issuer's board of directors and issued the Press Release. The Letter and the Press Release are attached hereto as Exhibit 99.2 and incorporated herein by reference. Except as otherwise described in the Prior Statement, this Amendment No. 2, the Joint Filing Agreement attached hereto as Exhibit 99.1 and the Letter and the Press Release attached hereto as Exhibit 99.2, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
Item 7 of the Prior Statement is hereby amended and restated in its entirety as follows: 99.1 Joint Filing Agreement, dated as of May 20, 2025 (incorporated by reference to Exhibit 1 to the Prior Statement filed by the Reporting Persons on May 20, 2025). 99.2 Letter and Press Release re: Potential Transaction, dated June 29, 2026.